U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07102706) titled 'Phase I Trial of GR1803 Injection in Patients With RRMM' on July 30.
Brief Summary: All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 52 weeks or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.
Study Start Date: May 27, 2022
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma (MM)
Intervention:
DRUG: GR1803 injection
weekly d...